Literature DB >> 2573339

Modulation of the autonomic control of the failing heart.

H M Snow1.   

Abstract

The failing heart operates with an abnormal combination of heart rate, stroke volume, and enddiastolic volume. This mismatch becomes more evident during exercise of patients with heart failure, when an increase in cardiac output is achieved with higher heart rate, a lower stroke volume and a higher enddiastolic volume. Using the beta 1-adrenoceptor partial agonist xamoterol which lacks beta 2-adrenoceptor agonism the response of the heart to sympathetic stimulation can be modulated. At rest and low levels of exercise xamoterol provides an inotropic support of the heart, whereas it reduces inappropriate tachycardia at higher levels. Thereby, xamoterol tends to normalize the balance of the inotropic and chronotropic control of the failing heart, because cardiac output is increased with a more normal combination of heart rate, stroke volume, and filling pressure. The beneficial effects of xamoterol are discussed as being especially important for failing ischemic hearts, because the balance between energy supply and energy demand may be improved by xamoterol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573339     DOI: 10.1007/BF02650356

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  26 in total

1.  Circulatory effects of practolol.

Authors:  R E Finegan; A M Marlon; D C Harrison
Journal:  Am J Cardiol       Date:  1972-03       Impact factor: 2.778

2.  Autonomic control of cardiac pacemaker activity and atrioventricular transmission.

Authors:  M N Levy; H Zieske
Journal:  J Appl Physiol       Date:  1969-10       Impact factor: 3.531

3.  Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding.

Authors:  N Cook; A Richardson; D B Barnett
Journal:  Eur J Pharmacol       Date:  1984-03-02       Impact factor: 4.432

4.  Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist.

Authors:  J M Detry; P M Decoster; L A Brasseur
Journal:  Eur Heart J       Date:  1983-08       Impact factor: 29.983

5.  Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.

Authors:  H Sato; M Inoue; T Matsuyama; H Ozaki; T Shimazu; H Takeda; Y Ishida; T Kamada
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

6.  Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.

Authors:  J J Barlow; B G Main; H M Snow
Journal:  J Med Chem       Date:  1981-03       Impact factor: 7.446

7.  Response to upright exercise after myocardial infarction.

Authors:  M Hetherington; K K Teo; R G Haennel; R E Rossall; T Kappagoda
Journal:  Cardiovasc Res       Date:  1987-06       Impact factor: 10.787

8.  Hemodynamic response to graded exercise after chronic beta-adrenergic blockade.

Authors:  T Reybrouck; A Amery; L Billiet
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-02

9.  Effects of xamoterol (ICI 118,587) in asthmatic patients.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

10.  Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.

Authors:  G Jennings; A Bobik; C Oddie; R Restall
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.